Standard Bariatrics receives sleeve gastrectomy indication from FDA for STANDARD CLAMP


Standard Bariatrics, an innovator of surgical devices, has received a sleeve gastrectomy indication from the Food and Drug Administration (FDA) for the STANDARD CLAMP. “Standard Bariatrics is committed to creating superior bariatric surgery outcomes through device innovations. The acceptance of the supplemental data by the FDA to expand the U.S. indications of the STANDARD CLAMP is another significant milestone for the Company,” said Jonathan Thompson MD, Founder and Chief Medical Officer of Standard Bariatrics. “With the patient’s health top priority, we aimed to standardize an anatomy-based approach to sleeve gastrectomy.”

Current techniques and device usage for laparoscopic sleeve gastrectomy are highly variable, and studies show that freehand sleeve gastrectomy techniques can yield inconsistent pouch anatomy. Because of challenges, bariatric surgeons have been able to achieve the ideal sleeve anatomy less than 40% of the time, resulting in inconsistent outcomes for the patient including reduced weight loss and GERD.

The STANDARD SLEEVE addresses issues of inconsistent surgical anatomy through an anatomy-based approach. Performed with the first-of-its-kind, purpose-built, disposable device, the STANDARD CLAMP allows fixation of the full cut line across the entire stomach, enabling surgeons to plan and hold the staple line prior to dividing the stomach during sleeve gastrectomy.

“The STANDARD CLAMP allows planning, visualization and stabilization of the full staple line before staple firing, enabling bariatric surgeons to confidently achieve ideal surgical sleeve anatomy consistently,” said Ronald Galovich, Chief Commercial Officer of Standard Bariatrics. “We are excited about the opportunity to bring the STANDARD CLAMP to every bariatric surgeon performing the sleeve gastrectomy procedure.”​

Kettlebell exercises: the best kettlebell exercises for a sweat-inducing, whole-body workout

UChicago expert sheds light on pancreatic neuroendocrine tumors